A203400 Stock Overview
Operates as a pharmaceutical biotech Company in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ABION Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,480.00 |
| 52 Week High | ₩13,000.00 |
| 52 Week Low | ₩4,710.00 |
| Beta | 1.23 |
| 11 Month Change | -12.92% |
| 3 Month Change | -20.43% |
| 1 Year Change | 52.81% |
| 33 Year Change | -30.74% |
| 5 Year Change | 1.49% |
| Change since IPO | 28.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| A203400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.4% | -1.5% | 0.9% |
| 1Y | 52.8% | 23.1% | -3.4% |
Return vs Industry: A203400 exceeded the KR Biotechs industry which returned 23.1% over the past year.
Return vs Market: A203400 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A203400 volatility | |
|---|---|
| A203400 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A203400's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A203400's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 38 | Young-Gi Shin | abionbio.com |
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters.
ABION Inc. Fundamentals Summary
| A203400 fundamental statistics | |
|---|---|
| Market cap | ₩188.94b |
| Earnings (TTM) | -₩45.27b |
| Revenue (TTM) | ₩829.22m |
227.9x
P/S Ratio-4.2x
P/E RatioIs A203400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A203400 income statement (TTM) | |
|---|---|
| Revenue | ₩829.22m |
| Cost of Revenue | ₩810.90m |
| Gross Profit | ₩18.33m |
| Other Expenses | ₩45.29b |
| Earnings | -₩45.27b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.79k |
| Gross Margin | 2.21% |
| Net Profit Margin | -5,459.58% |
| Debt/Equity Ratio | 254.1% |
How did A203400 perform over the long term?
See historical performance and comparison